Somatropin + Ethinyl estradiol + Medroxyprogesterone acetate
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Turner Syndrome
Conditions
Turner Syndrome
Trial Timeline
Feb 1, 1989 → Dec 1, 2007
NCT ID
NCT00191113About Somatropin + Ethinyl estradiol + Medroxyprogesterone acetate
Somatropin + Ethinyl estradiol + Medroxyprogesterone acetate is a phase 3 stage product being developed by Eli Lilly for Turner Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00191113. Target conditions include Turner Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00191113 | Phase 3 | Completed |
Competing Products
10 competing products in Turner Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Somatropin | Eli Lilly | Phase 3 | 77 |
| Humatrope | Eli Lilly | Approved | 85 |
| 17 beta estradiol | Eli Lilly | Phase 3 | 77 |
| r-hGH | Merck | Approved | 85 |
| Somapacitan + Norditropin® | Novo Nordisk | Phase 3 | 76 |
| estradiol | Novo Nordisk | Approved | 84 |
| Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch | Novo Nordisk | Phase 1 | 32 |
| somatotropin | Pfizer | Pre-clinical | 22 |
| Lonapegsomatropin + Somatropin | Ascendis Pharma | Phase 2 | 49 |
| Somatropin (rDNA origin) | Ipsen | Phase 3 | 74 |